Healthcare Sector

JNJ

Market Tracker

$238.94
-2.38
(-0.98%)
7:00 pm
Next Earnings: (est.) 07/20/23 12:00 am
  • JNJ (Selected)

    Johnson & Johnson

JNJ Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

JNJ Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

JNJ Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

JNJ Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

JNJ Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

JNJ Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
04/10/2026 CALL $242.50 1,466 +622 +73.70%
09/18/2026 CALL $280.00 2,530 +426 +20.25%
09/18/2026 PUT $210.00 3,862 +253 +7.01%
06/18/2026 PUT $210.00 3,690 +247 +7.17%
10/16/2026 PUT $210.00 627 +237 +60.77%
05/15/2026 CALL $250.00 2,312 +180 +8.44%
04/10/2026 PUT $235.00 1,310 -29 -2.17%
04/17/2026 PUT $230.00 6,560 -30 -0.46%
06/18/2026 PUT $190.00 1,380 -38 -2.68%
04/17/2026 CALL $270.00 967 -59 -5.75%
06/18/2026 PUT $220.00 2,641 -78 -2.87%
04/10/2026 CALL $245.00 1,116 -262 -19.01%

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

JNJ Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 2.55% 79.47M 12.56B
Vanguard 500 Index Fund 1.94% 60.44M 9.55B
Fidelity 500 Index Fund 0.92% 28.66M 4.53B
SPDR S&P 500 ETF Trust 0.91% 28.31M 4.47B
iShares Core S&P 500 ETF 0.75% 23.33M 3.69B
Vanguard Index-Value Index Fund 0.72% 22.6M 3.57B
Select Sector SPDR Fund-Health Care 0.68% 21.24M 3.36B
Vanguard Institutional Index Fund-Institutional Index Fund 0.59% 18.32M 2.9B
Vanguard Specialized-Dividend Appreciation Index Fund 0.53% 16.62M 2.63B
Washington Mutual Investors Fund 0.40% 12.37M 1.96B

JNJ News

  • Stocks Rallied After President Donald Trump's Ceasefire in Iran. Here's How to Invest Now.

    04/11 05:06 am

    The Motley Fool

    Read more
  • Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032

    04/10 04:43 am

    GlobeNewswire Inc.

    Read more
  • Could Buying This Dividend Pharma Stock Today Set You Up for Life?

    04/09 08:15 pm

    The Motley Fool

    Read more
  • Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing Sector

    04/07 03:18 pm

    The Motley Fool

    Read more
  • Microsoft Is Now The Biggest Deadweight On S&P 500 — And Exxon Is What Nvidia Used To Be

    04/07 12:17 pm

    Benzinga

    Read more
  • Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime

    04/06 01:20 pm

    Investing.com

    Read more
  • JEPI vs. JEPQ: Which Is the Better Buy in April?

    04/04 12:30 am

    The Motley Fool

    Read more
  • This Healthcare Stock Barely Flinches During Market Sell-Offs

    04/02 06:14 am

    The Motley Fool

    Read more
  • Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report

    04/02 04:44 am

    Benzinga

    Read more
  • Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

    04/01 01:00 pm

    GlobeNewswire Inc.

    Read more
  • The Dividend King That's Raised Its Payout for 63 Consecutive Years

    03/31 01:30 pm

    The Motley Fool

    Read more
  • New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting

    03/28 04:05 am

    GlobeNewswire Inc.

    Read more
  • Is Intuitive Surgical a Buy Right Now?

    03/27 05:15 pm

    The Motley Fool

    Read more
  • The Newest Big Idea From Elon Musk: Terafab

    03/27 02:16 pm

    The Motley Fool

    Read more
  • A Q2 2026 Playbook for Navigating Market Uncertainty

    03/26 05:09 pm

    Investing.com

    Read more
  • Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process

    03/25 01:02 pm

    Benzinga

    Read more
  • Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie

    03/19 08:25 am

    Benzinga

    Read more
  • Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic

    03/17 04:00 am

    GlobeNewswire Inc.

    Read more
  • Defensive Sectors: Are Utilities, Staples, and Health Care Signaling Trouble?

    03/17 02:44 am

    Investing.com

    Read more
  • BIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon

    03/16 06:00 am

    GlobeNewswire Inc.

    Read more
  • HDV vs. SCHD: Which Dividend ETF Is Best?

    03/13 02:17 pm

    The Motley Fool

    Read more
  • Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support

    03/13 07:00 am

    GlobeNewswire Inc.

    Read more
  • The Largest Stock Holding in the Vanguard High Dividend Yield ETF Just Delivered Blowout Earnings. Here's Why the ETF Is Crushing the S&P 500 in 2026 and Worth Buying in March.

    03/13 06:35 am

    The Motley Fool

    Read more
  • FDVV vs. HDV: 2 High-Dividend ETFs With Opposite Ideas About Big Tech

    03/12 05:13 pm

    The Motley Fool

    Read more
  • Growing Your Income vs. Maximizing It Now: The Core Difference Between VIG and HDV

    03/12 03:23 pm

    The Motley Fool

    Read more
  • The Best Dividend Stocks to Buy and Hold Forever

    03/12 01:30 pm

    The Motley Fool

    Read more
  • Income-Oriented ETFs: VYM Offers Greater Diversification, While HDV Boasts a Higher Yield

    03/12 01:07 pm

    The Motley Fool

    Read more
  • Demande d’autorisation de mise sur le marché de TECVAYLI®▼ (teclistamab) en monothérapie soumise à l’EMA pour le myélome multiple en rechute ou réfractaire après au moins une ligne de traitement antérieure

    03/12 07:00 am

    GlobeNewswire Inc.

    Read more
  • Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence

    03/12 03:45 am

    GlobeNewswire Inc.

    Read more
  • Like Dividend Income? This Groundbreaking ETF Changed the Game for Investors

    03/11 12:03 pm

    The Motley Fool

    Read more
  • My Top 3 Dividend Kings to Buy for March 2026

    03/10 12:14 pm

    The Motley Fool

    Read more
  • 2 No-Brainer Dividend Stocks to Buy in 2026

    03/08 12:27 pm

    The Motley Fool

    Read more
  • These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their Shareholders

    03/08 12:06 pm

    The Motley Fool

    Read more
  • Jobs Crash, War Flares: Smart Money Hides In These Stocks

    03/06 05:01 pm

    Benzinga

    Read more
  • FDA Clears Johnson & Johnson's Multiple Myeloma Combo Drug After Strong Survival Results

    03/06 09:53 am

    Benzinga

    Read more
  • Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market

    03/05 05:44 am

    GlobeNewswire Inc.

    Read more
  • 10 Stocks to Own as Middle East Tensions Drive Investors Toward Safety

    03/04 01:47 pm

    Investing.com

    Read more
  • AbbVie Says 55% Of Crohn's Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson

    03/02 01:28 pm

    Benzinga

    Read more
  • Antibiotics Market - 4.07% CAGR Forecast for 2026-2031 as Antimicrobial Innovation Strengthens Demand, Says Mordor Intelligence

    03/02 05:59 am

    GlobeNewswire Inc.

    Read more
  • A Symbol of Crisis: As Colorectal Cancer Deaths Rise, Fight CRC Installs United in Blue on the National Mall

    02/27 03:52 pm

    GlobeNewswire Inc.

    Read more
  • One in Three Rheumatologists View BMS’ Sotyktu as a Substantial Advance in Psoriatic Arthritis Ahead of March 6 FDA Decision, According to Spherix Global Insights Data

    02/27 01:31 pm

    GlobeNewswire Inc.

    Read more
  • Global Medical Device Cleaning Market Poised for Strong Growth as Infection Control Mandates and Reprocessing Technologies Accelerate Adoption: Verified Market Research®

    02/27 11:55 am

    GlobeNewswire Inc.

    Read more
  • Advanced Drug Delivery Market to Grow 10.2% Annually Through 2030

    02/25 01:54 pm

    GlobeNewswire Inc.

    Read more
  • Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

    02/25 11:17 am

    Investing.com

    Read more
  • ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock

    02/25 09:10 am

    The Motley Fool

    Read more
  • 3 Vanguard ETFs to Buy That Are Crushing the S&P 500 in 2026

    02/23 01:35 pm

    The Motley Fool

    Read more
  • Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio

    02/22 02:02 pm

    The Motley Fool

    Read more
  • J&J Eyes Mega Sale Of DePuy Synthes In Orthopedics Breakup Push

    02/20 07:53 am

    Benzinga

    Read more
  • ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine

    02/18 06:59 pm

    GlobeNewswire Inc.

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: